Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Pharmacy owner in deadly 2012 U.S. meningitis outbreak gets 1 year in prison

Published 12/01/2022, 01:12 PM
Updated 12/01/2022, 03:10 PM
© Reuters. FILE PHOTO: Gregory Conigliaro, a co-owner of the now-defunct New England Compounding Center, enters the federal court in Boston, Massachusetts, U.S., December 7, 2018.  REUTERS/Nate Raymond/

By Nate Raymond

BOSTON (Reuters) - A co-owner of a Massachusetts compounding pharmacy whose mold-tainted drugs sparked a deadly fungal meningitis outbreak in 2012 was sentenced on Thursday to one year in prison for deceiving regulators to avoid federal oversight before the tragedy.

Gregory Conigliaro was sentenced by U.S. District Judge Richard Stearns in Boston after a federal appeals court last year revived his conviction for conspiring to defraud the U.S. Food and Drug Administration ahead of the outbreak.

He was among 14 people associated with Framingham, Massachusetts-based NECC who were indicted after mold-tainted steroids it produced sickened 793 people nationally, including more than 100 who died.

The defendants included Barry Cadden, NECC's ex-president, and Glenn Chin, its former supervisory pharmacist, who were convicted of racketeering and fraud and are serving prison sentences of 14-1/2 and 10-1/2 years, respectively.

Conigliaro, Cadden's brother-in-law, was not charged over the tainted drugs. But Assistant U.S. Attorney Amanda Strachan said his lies to regulators in the decade beforehand ensured NECC remained open, allowing the tragedy to unfold.

"He was responsible for keeping that business open until they got caught," Strachan said.

Prosecutors said Conigliaro, 57, conspired with others at NECC to deceive the FDA into believing it was operating like a conventional pharmacy subject to state oversight and not like a drug manufacturer subject to tougher federal oversight.

Prosecutors said Conigliaro in particular misled the FDA into believing it was dispensing drugs pursuant to valid, patient-specific prescriptions like a typical pharmacy when it was actually shipping drugs nationally without them.

A jury in 2018 found Conigliaro guilty, but Stearns threw out his conviction, saying it was legally impossible for Conigliaro to have impeded the FDA's functions. A federal appeals court disagreed and reversed that decision in 2021.

© Reuters. FILE PHOTO: Gregory Conigliaro, a co-owner of the now-defunct New England Compounding Center, enters the federal court in Boston, Massachusetts, U.S., December 7, 2018.  REUTERS/Nate Raymond/

In addition to prison, Conigliaro must pay a $40,000 fine.

He told Stearns that had he known about the "horrible" conduct that occurred in the so-called clean rooms in which NECC's drugs were produced, "I would have done everything and anything possible to stop it, period."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.